Ecor1 Capital, Llc Purchases 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc bought 6,646 shares of the stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc acquired 65,184 shares of AnaptysBio stock. The stock was acquired at an average price of $12.92 per share, with a total value of $842,177.28.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB traded up $0.12 during trading hours on Thursday, reaching $13.36. The stock had a trading volume of 465,990 shares, compared to its average volume of 390,740. The firm’s 50 day moving average is $20.47 and its 200-day moving average is $28.60. AnaptysBio, Inc. has a 1 year low of $12.51 and a 1 year high of $41.31. The stock has a market capitalization of $406.53 million, a price-to-earnings ratio of -2.20 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. Analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on ANAB shares. Truist Financial reduced their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Guggenheim dropped their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Wells Fargo & Company dropped their price objective on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.45.

Institutional Trading of AnaptysBio

Several large investors have recently bought and sold shares of ANAB. Rhumbline Advisers lifted its holdings in shares of AnaptysBio by 1.8% in the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 525 shares in the last quarter. Algert Global LLC raised its position in shares of AnaptysBio by 11.8% during the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares during the last quarter. nVerses Capital LLC raised its position in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the last quarter. Values First Advisors Inc. purchased a new stake in AnaptysBio in the 3rd quarter valued at approximately $49,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.